期刊文献+

新城疫病毒样颗粒疫苗研究进展 被引量:2

Research Progress of Newcastle Disease Virus-Like Particles Vaccine
在线阅读 下载PDF
导出
摘要 病毒样颗粒是指利用异源宿主系统表达的病毒,结构蛋白自行组装成不含病毒基因组、不能复制、不具有感染能力的病毒样蛋白颗粒。病毒样颗粒具备构象逼真、安全、稳定、可刺激体液和细胞免疫应答、作为载体表达其他抗原以及可设计成区分自然感染与免疫接种等诸多优点。有研究表明,新城疫病毒样颗粒可用来研制针对新城疫流行变异株的高效疫苗。作者就新城疫病毒样颗粒相关研究进展进行较为详尽的综述,以期为中国新城疫病毒样颗粒疫苗的研究提供参考。 The virus like-particles(VLPs)is the virus like protein particles,expressed by a heterologous host system,use viral structural proteins to assemble themselves,non viral genome,can not be copied,have no infection ability.Virus like-particles has many advantages such as realistic conformation,safe,stable,can stimulate humoral and cellular immune responses,as a carrier to express other antigens and can be designed to distinguish between natural infection and vaccination.Some studies have indicated that the Newcastle disease virus particles can be used to develop a vaccine against Newcastle disease.In this paper,the author makes a detailed review on the research progress of Newcastle disease virus particles,in order to provide reference for the study of the vaccine of Newcastle disease virus like-particles in China.
作者 马博文
机构地区 甘肃省中医学校
出处 《畜牧兽医杂志》 2017年第2期19-20,共2页 Journal of Animal Science and Veterinary Medicine
关键词 新城疫病毒 病毒样颗粒 疫苗 Newcastle Disease Virus Virus-like particles Vaccine
  • 相关文献

参考文献6

二级参考文献68

  • 1Fenouillet E, Barbouche R, Jones I M. Cell entry by enveloped viruses: redox considerations for HIV and SARS-coronavirus. AntioxidRedox Signal, 2007, 9: 1009-1034.
  • 2Devico A, Fouts T, Lewis G K, et al. Antibodies to CD4-induced sites in HIV gp120 correlate with the control of SHIV challenge inmacaques vaccinated with subunit immunogens. Proc Natl Acad Sci USA, 2007, 104: 17477-17482.
  • 3Doms R W, Moore J P. HIV-1 membrane fusion: Targets of opportunity. J Cell Biol, 2000, 151: F9-F14.
  • 4Wyatt R, Sodroski J. The HIV-1 envelope glycoproteins: Fusogens, antigens, and immunogens. Science, 1998, 280: 1884-1888.
  • 5Tagliamonte M, Tornesello M L, Buonaguro F M, et al. Conformational HIV-1 envelope on particulate structures: a tool for chemokinecoreceptor binding studies. J Transl Med, 2011, 9(Suppl 1): S1.
  • 6Buonaguro L, Buonaguro F M, Tornesello M L, et al. High efficient production of Pr55(gag) virus-like particles expressing multiple HIV-1epitopes, including a gp120 protein derived from an Ugandan HIV-1 isolate of subtype A. Antiviral Res, 2001, 49: 35-47.
  • 7Gheysen D, Jacobs E, D E Foresta F, et al. Assembly and release of HIV-1 precursor Pr55gag virus-like particles from recombinantbaculovirus-infected insect cells. Cell, 1989, 59: 103-112.
  • 8Yamshchikov G V, Ritter G D, Vey M, et al. Assembly of SIV virus-like particles containing envelope proteins using a baculovirusexpression system. Virology, 1995, 214: 50-58.
  • 9Wagner R, Deml L, Fliessbach H, et al. Assembly and extracellular release of chimeric HIV-1 Pr55gag retrovirus-like particles. Virology,1994, 200: 162-175.
  • 10Wang B Z, Liu W, Kang S M, et al. Incorporation of high levels of chimeric human immunodeficiency virus envelope glycoproteins intovirus-like particles. J Virol, 2007, 81: 10869-10878.

共引文献38

同被引文献22

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部